40^th International Conference on Drug Discovery and Drug delivery system August 23-24, 2023 Abbotsford, Canada

Dr. Stinchcomb received her PhD in Pharmaceutics from University of Michigan. She completed her Post-Doctoral Fellowship (Biopharmaceutics) from University of California, San Francisco. In 2010 she was honoured with "Kentucky Entrepreneur Hall of Fame" & "Springboard Portfolio Company - All Things Life Sciences". In 2011 as AAPS Fellow.

Dr. Stinchcomb’s research is focused on transdermal prodrugs, microneedle-enhanced delivery, and translational research models for public-private partnerships.

Dr. Moses Oyewumi is an Assistant Professor in the Department of Pharmaceutical Sciences at the Northeast Ohio Medical University College of Pharmacy. Dr. Oyewumi earned his Ph.D. from the University of Kentucky in 2003 and completed post-doctoral training at the University of Kentucky and at the University of Iowa in 2005. prior to joining NEOMED, Dr. Oyewumi was a Scientist, Pharmaceutics R&D for four years in a pharmaceutical industry. He is having many patents in his name.

Design, development and application of novel nanoparticulate/microparticulate delivery systems. Assessment of novel drug delivery systems using in-vitro and in-vivo models. Targeted drug delivery systems in cancer, neuroprotection and neurodegeneration. Nasal drug delivery systems in CNS diseases. Oral delivery of macromolecules.

Dr. Vinayagam Kannan is a Senior Scientist, Formulation R&D at Par Sterile Products, LLC. He has a Ph.D. in Pharmaceutical Sciences from The University of Tennessee Health Science Center (UTHSC). He obtained master’s degree in Pharmaceutics from National Institute of Pharmaceutical Education and Research (NIPER), India and bachelor’s degree in Pharmacy from The Tamil Nadu Dr.MGR Medical University, India. He has an excellent academic record with several awards and fellowships. He was inducted into The Rho Chi Honor Society in the year 2009 for his academic excellence.

Injectable and ophthalmic drug product development, pre-formulation, solubilization techniques, lyophilization, targeted drug delivery, nanoparticulate systems including liposomes, design of experiments (DOE), Quality by Design (QbD), extractables/leachables, and salt selection/screening.

Dr. Richard A. Gemeinhart received his PhD in Pharmaceutics from Purdue University. From 1995 to present He is a memeber Rho Chi Pharmacy Honor Society. In 2006 he was invited to The Society For Biomaterials Young Investigator. In 2006-2007 he was awarded with Hans W. Vahlteich Scholar.

Dr. Gemeinhart's Research interest lies in Biomaterials for Tissue Regeneration, Micro/Nanostructures, Drug Conjugates for Cancer Therapy & many others.

Dr. Bivash Mandal is currently working as a Sr. Research Specialist at Plough Center for Sterile Drug Delivery Systems at the University of Tennessee Health Science Center, Memphis, TN, USA. He obtained Bachelor of Pharmacy degree and Masters of Pharmacy degree (major in Pharmaceutics) from Jadavpur University, India. He pursued MS degree in Pharmaceutical Sciences with Industrial Pharmacy major from University of Toledo, Ohio, USA. He completed his Ph.D. degree in Pharmaceutics from the University of Tennessee Health Science Center, Memphis, TN, USA. Prior to joining the MS program, he worked as a scientist in the formulation R & D department at Dr. Reddy’s Laboratories Ltd., India. He has authored in many scientific peer-reviewed articles, patent application and conference presentations. He serves as the editorial board members, reviewers in many pharmaceutical science journals and received prestigious AAPS graduate research award.

Advanced and novel drug delivery systems, nanomedicines including liposomes, antibody conjugated nanoparticles, polymeric nanoparticles, injectables and oral solid drug product development, pre-formulation, formulation, solubilization techniques, lyophilization, parenteral manufacturing, analytical method development and validation.

Dr. Boudinot received his PhD. in Pharmaceutics from State University of New York in 1985. In 1979 - 1980 he worked as a Research Technician, Clinical Pharmacokinetics Laboratory at Millard Fillmore Hospital. In 1980 - 1985, He joined as Graduate Assistant, Department of Pharmaceutics, School of Pharmacy, State University of New York at Buffalo. In 1985 - 1990 He moved to University of Georgia to join as Assistant Professor of Pharmaceutics, College of Pharmacy. In 1986 - 2002 He was promoted to Faculty of Gerontology, University of Georgia Gerontology Center. From 2002 to present he was promoted to several posts such as Associate Professor, Head of Department, Associate Dean & Senior Associate Dean. He was also a part of Faculty of Interdisciplinary Graduate Program in Toxicology, University of Georgia. Currently He is the Dean of Graduate School, Virginia Commonwealth University.

Dr. Boudinot's research focuses on pharmacokinetics, biopharmaceutics, drug metabolism and pharmacodynamics in drug discovery and development. Research involves characterizing physicochemical properties of novel therapeutic agents, developing bioanalytical methodologies, conducting preclinical pharmacokinetic studies and developing pharmacokinetic models for interspecies scale up. Current work is focused on the pharmacokinetics of large molecular weight polyanionic compounds and characterization of physiological mechanisms involved in drug distribution and elimination.

Dr. Sudip K. Das is Professor of Pharmaceutics at the College of Pharmacy & Health Sciences, Butler University, Indianapolis, IN, where he also served as the chair of the Department of Pharmaceutical Sciences from 2004-09. After obtaining an undergraduate degree in pharmacy and MPharm and PhD in Pharmaceutics from India, Dr. Das pursued postgraduate training as a UNIDO scholar in pharmaceutical technology at the State University of Gent, Belgium. He continued postdoctoral training at The University of Queensland, Australia, following which he accepted a faculty position at Memorial University of Newfoundland, Canada. Before joining Butler, Dr. Das held faculty positions in pharmacy colleges at Nova Southeastern University and Idaho State University. Dr. Das has over twenty years of teaching experience in the professional pharmacy and graduate programs in the USA and Canada. He has supervised a number of postdoctoral, graduate and undergraduate research students, and was the key faculty responsible for the revitalization of the graduate program and research infrastructure in pharmaceutical sciences at Butler University Dr. Das has over 150 research publications, review articles, patents, proceedings, conference presentations, and book chapters, is a recipient of multiple awards/honors, and has secured extramural research funding from NIH, PDA, etc., and the pharmaceutical industry. Dr. Das has been an active member of AACP since 1994, where he became an AACP Leadership Fellow (2005), and served as the chair-elect, chair and immediate past chair of the Teachers of Pharmaceutics Section (2006-09). As the section chair, he strongly advocated the professional growth of the pharmaceutics faculty workforce, and the development of contemporary pharmaceutics curricula. From 2008-11, Dr. Das served as the founding chair and immediate past chair of the AACP Council of Sections, where he led the task of developing the mission and goals of the new council, and created various task forces supporting the missions of the AACP sections. He has also served on the AACP Board of Directors (2008-11), AACP Research & Graduate Affairs and the Bylaws and Policy Development Committees, along with various AACP Task Forces. Dr. Das is also an active member of AAPS (since 1991) and CRS (Controlled Release Society, since 1987). He has served on many committees of the PDD/PPB and BIOTEC sections of AAPS. Since 2004, he has served on several study sections for the NIH - Center for Scientific Review and continues to serve on the editorial boards of AJPE and Therapeutic Delivery.

His current research involves targeted delivery of siRNA and nano-composites for the treatment of cancer and neurodegenerative diseases.

Dr. Lane's areas of expertise include membrane transport, biophysical approaches towards the elucidation of drug-drug, drug-excipient and drug-membrane interactions, mechanisms of drug absorption, transdermal drug delivery, topical drug delivery, percutaneous absorption, peptide and protein formulation, ungual drug absorption, buccal drug absorption. Dr Lane's major research interests are in the development of optimal drug formulations for effective delivery of therapeutics, with special reference to skin, nail and to mucus membranes. Her research group uses a range of biophysical techniques to probe the mechanisms of skin and nail penetration and modulation.

Dr. Lane's areas of expertise include membrane transport, biophysical approaches towards the elucidation of drug-drug, drug-excipient and drug-membrane interactions, mechanisms of drug absorption, transdermal drug delivery, topical drug delivery, percutaneous absorption, peptide and protein formulation, ungual drug absorption, buccal drug absorption. Dr Lane's major research interests are in the development of optimal drug formulations for effective delivery of therapeutics, with special reference to skin, nail and to mucus membranes. Her research group uses a range of biophysical techniques to probe the mechanisms of skin and nail penetration and modulation.

Dr. Davies received his undergraduate degree in Pharmacy from the University of Alberta in 1991. In 1996, he completed his Ph.D. in pharmaceutical sciences, specializing in pharmacokinetics, at the University of Alberta. From 1995 to 1998, he undertook postdoctoral training in pharmacology and toxicology at the University of Calgary. He then joined the University of Sydney as a lecturer in 1998. In 2002, he returned to North America to join the Washington State University’s (WSU) College of Pharmacy as an academic staff member, where he has held the positions of Director of the Pharmaceutical Sciences Graduate Program, as well as Director of Professional and Undergraduate Research and Director of Summer Undergraduate Research Fellowship program. Under his direction he has been involved in several administrative and operational initiatives including: strategic planning, faculty accreditation review processes; organizing the College retreat, establishment of a pharmaceutical sciences graduate program; and initiated the development of a comprehensive knowledge exam for the College’s PharmD program. Dr. Davies also championed the development of a College wide Pharmacy Research Day and has played key roles in faculty and graduate student recruitment and success. He has been active on numerous university-wide committees, including service as a member of WSU’s Faculty Senate and Chair of the Institutional Animal Care and Use Committee. Dr. Davies has strived to maintain the highest standard of teaching and research, and his achievements in both areas have been recognized through numerous awards and honours including several from the United States Pharmacopeia. He has taught at the undergraduate and graduate levels, and has an ongoing and significant commitment toward graduate supervision and training. He has been at the forefront of the use of technology in the classroom, has re-engineered curricular content and maintained a high standard in student mentoring. Dr. Davies also maintains an active and highly collaborative externally-funded research program, focused on pharmacokinetics and drug delivery as well as basic and clinical pharmaceutical sciences which have attracted National Institutes of Health and Industry funds. He holds five patent applications and has disseminated his work broadly through numerous journal publications, book chapters, abstracts, and invited conference presentations.

Dr. Davies' research program in the Faculty of Pharmacy aims to investigate the factors that influence variability in drug response through an understanding of drug delivery (nanomedicine) and disposition (pharmacokinetics) as well as action to optimize the use of anti-oxidant and anti-cancer agents. The Davies laboratory explores factors affecting the dissolution, stability, release and safety and efficacy of anti-oxidant nutraceutical and anti-cancer drugs, the role of liver and renal metabolism in determining effects of drugs

Associate professor of organic chemistry, Faculty of Specific Education, Ain Shams University.

Organic Chemistry

Dr. Hirofumi Takeuchi is professor of department of pharmaceutical technology, Gifu Pharmaceutical University. e received his B.S. (1979), M.S. (1981) and Ph.D (1984) in pharmaceutical sciences from Kyoto University. He joined Gifu Pharmaceutical University GPUas a faculty member in 1984, and became Lecture in 1988. He is now Professor of GPU and the dean of graduate school of GPU. He spent one year as a visiting scientist at Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, in 1989-1990. e is now working for several scientific societies such as for the vice president of The Society of Powder Technology, Japan, and CRS (Controlled Release Society) Board of Scientific Advisors and so on.

His research interest includes Modified Drug delivery & Drug release, Powder Technology.

Dr. Bo Michniak-Kohn is Academically appointed as Professor of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey.

Optimization of topical, transdermal and buccal drug delivery. Development of novel permeation models and computational modeling. Design and evaluation of novel dermal penetration enhancers and retardants & their structure-activity relationships. Design and testing of novel formulations for topical and transdermal drug delivery including creams, emulsions, gels and micro-and nano-carrier systems. Treatment & therapeutics for dermatological diseases such as atopic dermatitis, melanoma and psoriasis. Physical approaches to enhancing dermal drug delivery: iontophoresis, microneedles as well as formulation optimization. Visualization of drug transport pathways in skin using Raman, Fourier Transform Infra-Red spectroscopy, electron and confocal microscopy. Development of novel human tissue cultured skin equivalents for permeability testing. Computational approaches to predicting skin transport of drugs. Optimization of buccal drug delivery. Pharmacokinetics and ADME studies in animals and humans.

Dr. Kasturi Pawar is a pharmaceutics professional with Doctorate in Pharmaceutics and over 6 years of research experience in the areas of topical, transdermal oral formulation development and drug delivery, microneedles- and iontophoresis-assisted delivery, biomaterial synthesis, and analytical method development and validation using HPLC. Dr. Pawar is currently employed with Valeant Pharmaceuticals International as a Principal Research Scientist in Formulation development department. Prior to Valeant Pharmaceuticals International, Dr. Pawar has also held Lead Formulation Scientist positions in her previous jobs at Tioga Research Inc. and G&W Laboratories. She has earned her PhD from Auburn University, AL in 2013, and her Masters and Bachelors from India in 2007 and 2005, respectively. Prior to coming to USA, she was working as a Research Scientist with Sandoz Pvt. Ltd in India. Dr. Pawar has extensive experience working with challenging formulations and providing innovative ideas to troubleshoot the challenges. She has worked in collaboration with groups across the country, and authored and co-authored 6 research papers and 2 review papers, and presented her research work in 13 poster and oral presentations in the several national and international conferences. She has won several awards and honors in her career. She is currently serving as an active reviewer at the Annual National Meetings of American Association of Pharmaceutical Scientists. She is also a peer reviewer for Journal of Controlled Release, International Journal of Pharmaceutics, Journal of Pharmaceutical Sciences, Current Drug Delivery, Dove Medical Press Articles and SciTechnol articles. She serves as an editorial board member for two journals, Journal of Innovations in Applied Pharmaceutical Science and Journal of Innovations in Pharmaceuticals and Biological Sciences.

Kasturi Pawar research interests are topical/transdermal formulation development and delivery using active permeation techniques, solubility improvement of insoluble drugs, percutaneous penetration enhancement techniques, Oral solid formulation development and delivery, biomaterial synthesis, nanoparticle drug delivery and tissue engineering.

Alexander O. Terent’ev was born in Moscow, in 1973. He received his M.S. in Chemistry of Biologically Active Compounds from D. Mendeleev University of Chemical Technology of Russia, Moscow. Ph.D. degree (2000) and D.Sc. degree (2009) in Organic Chemistry in N.D. Zelinsky Institute of Organic Chemistry RAS. 2011 – Professor D. Mendeleev University of Chemical Technology of Russia. 2016 – Professor RAS. Head of the laboratory in N.D. Zelinsky Institute of Organic Chemistry RAS, Head of the laboratory in All-Russian Research Institute of Phytopathology. He published 3 chapters in books, 100 research papers, and 25 patents.

Organic chemistry

George Perry (born April 12, 1953 in Lompoc, California) is a neuroscientist recognized in the field of Alzheimer's disease research particularly for his work in oxidative stress. Dr. Perry has studied at many universities and holds multiple degrees including a Bachelor of Arts degree in Zoology from the University of California Santa Barbara and a PhD in Marine Biology from the University of California at San Diego. He is distinguished as one of the top Alzheimer’s disease researcherswith over 1000 publications, more than 60,000 citations, one of the top 100 most-cited scientists in Neuroscience & Behavior and one of the top 25 scientists in free radical research. Dr. Perry is a Semmes Foundation Distinguished chair in Neurobiology and is an active participant in many other scientific associations. In addition, Perry is an Editor of numerous scientific journals including Journal of Alzheimer’s Diseasewhich he founded in 1998. Today, Perry continues his love for research while working as Dean of the College of Sciences at The University of Texas at San Antonio.

role of redox active metals in mediating prooxidant and antioxidant properties

They have diverse leadership experience as health service professionals with significant accomplishments in all aspects of pharmacovigilance, clinical development, medical affairs, regulatory affairs, primary health care, project management & international health programs. I have vast experience working in diverse therapeutic areas including rare diseases, novel preventive & therapeutic vaccines, monoclonal antibodies, cardiovascular, oncology, neurology, nosocomial diseases, and generic and OTC medicines. I am currently working as Disease Area Cluster Lead for Biosimilars & Drug Delivery Devices at Pfizer. Currently, Pfizer has the largest biosimilar portfolio in the industry that includes projects on Inflammation, Oncology, Hematology, ophthalmology, etc. My past experience includes working as Associate vice president PV and Therapeutic Area Head (Rare Diseases) for Sanofi Genzyme, working as Senior Director & Director for vaccines PV at Sanofi Pasteur, and working as Medical Consultant for Apotex Inc Canada. Prior to joining the industry, I had worked as Joint Executive Director for the Pakistan Institute of Medical Sciences (PIMS), as Registrar of the Postgraduate medical institute PIMS, and as Deputy Director General, of the Ministry of Health Pakistan. I have also worked on various primary healthcare, public health, health planning & development programs as well World food, UNICEF, and WHO & JICA assisted programs on drug safety, emergency

Pharmacovigilance, Drug safety.

Tucker has advised major biotechnology firms on a broad range of sales and marketing strategy issues related to the biotech industry, with an emphasis on Oncology and Biosimilars. His experience has focused on global quantitative and qualitative primary market research and forecasting. Tucker was one of the founding members of ZS’s Biosimilars Vertical, and he has led over 30 training sessions across North America and Asia on this topic. Tucker holds an M.B.A. with honors from UCLA, and a B.A. with honors in from Stanford University

Biosimilars, Biologics, Oncology

Divya Chadha Manek is the Head of Business Development (Commercial) for the NIHR Clinical Research Network (CRN). Divya’s role is to maintain strategic relationships with Global and UK life sciences companies. Divya facilitates key discussions between life sciences industry and the Clinical Research Network. Divya provides advice and works collaboratively with companies on how they are able to tap into the Clinical Research Network services to ensure clinical studies are set up quickly and effi ciently so that they recruit to time and target. Divya also leads on ensuring that the Clinical Research Network is abreast of new study delivery innovations to ensure that the organization is evolving to service life sciences industry requirements.

Pharmaceuticals, Biologics, Biosimilars, Clinical Psychology, Clinical Research, Dementia Care